Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
Stock data | 2023 | Change |
---|---|---|
Price | $0.58 | N/A |
Market Cap | $5.05M | N/A |
Shares Outstanding | 8.71M | 0.11% |
Employees | 23.00 | N/A |
Shareholder Equity | 15.33M | -49.26% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.29 | N/A |
P/S Ratio | 13.66 | N/A |
P/B Ratio | 0.33 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.1259 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $370.00K | N/A |
Earnings | -$17.26M | N/A |
EPS | -1.98 | N/A |
Earnings Yield | -3.41 | N/A |
Operating Margin | -47.92 | N/A |
Net income margin | -46.65 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $20.31M | N/A |
Total Debt | $1.80M | N/A |
Cash on Hand | $16.01M | N/A |
Debt to Equity | 0.3251 | 218.17% |
Cash to Debt | $8.87 | -32.49% |
Current Ratio | $4.64 | -78.25% |